White Papers

ALS Studies and Lessons Learned From COVID-19

Central Nervous System (CNS), Rare Disease

The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.